CN106714793B - 琥珀酸脱氢酶抑制剂(SDHi’s) - Google Patents

琥珀酸脱氢酶抑制剂(SDHi’s) Download PDF

Info

Publication number
CN106714793B
CN106714793B CN201580035346.8A CN201580035346A CN106714793B CN 106714793 B CN106714793 B CN 106714793B CN 201580035346 A CN201580035346 A CN 201580035346A CN 106714793 B CN106714793 B CN 106714793B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
succinate
acceptable salt
succinate dehydrogenase
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580035346.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106714793A (zh
Inventor
爱德华·舒沙尼
托马斯·克里格
库罗什·塞伯帕塞
迈克尔·帕特里克·墨菲
洛林·沃克
克里斯蒂安·弗雷扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
United Kingdom Research and Innovation
Original Assignee
Cambridge Enterprise Ltd
United Kingdom Research and Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd, United Kingdom Research and Innovation filed Critical Cambridge Enterprise Ltd
Publication of CN106714793A publication Critical patent/CN106714793A/zh
Application granted granted Critical
Publication of CN106714793B publication Critical patent/CN106714793B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580035346.8A 2014-07-03 2015-07-03 琥珀酸脱氢酶抑制剂(SDHi’s) Expired - Fee Related CN106714793B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1411937.4 2014-07-03
GBGB1411937.4A GB201411937D0 (en) 2014-07-03 2014-07-03 Succinate dehydrogenase inhibitors (SDH's)
PCT/GB2015/051949 WO2016001686A1 (en) 2014-07-03 2015-07-03 SUCCINATE DEHYDROGENASE INHIBITORS (SDHi's)

Publications (2)

Publication Number Publication Date
CN106714793A CN106714793A (zh) 2017-05-24
CN106714793B true CN106714793B (zh) 2020-12-01

Family

ID=51410633

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580035346.8A Expired - Fee Related CN106714793B (zh) 2014-07-03 2015-07-03 琥珀酸脱氢酶抑制剂(SDHi’s)

Country Status (10)

Country Link
US (1) US10603298B2 (https=)
EP (1) EP3164126B1 (https=)
JP (1) JP2017519020A (https=)
CN (1) CN106714793B (https=)
AU (1) AU2015282424A1 (https=)
CA (1) CA2953709A1 (https=)
GB (1) GB201411937D0 (https=)
SG (1) SG11201610588UA (https=)
WO (1) WO2016001686A1 (https=)
ZA (1) ZA201608844B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200375963A1 (en) * 2017-02-10 2020-12-03 Health Research, Inc. Targeting mitochondrial complex ii to reduce effects of chronic hypoxia
WO2019139831A1 (en) * 2018-01-10 2019-07-18 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using succinate
WO2020041470A1 (en) * 2018-08-21 2020-02-27 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods of metabolic regulation of mitochondria for treating neural injury and neurological disorders using dsh inhibitors
CN109793760B (zh) * 2019-02-13 2022-07-19 中国人民解放军总医院 琥珀酸弧菌属在预防或治疗高原病药物中的用途
GB201918022D0 (en) * 2019-12-09 2020-01-22 Cambridge Entpr Ltd Treatment or prevention of Ischaemic Stroke Reperfusion Injury
US11813239B2 (en) * 2020-02-18 2023-11-14 Wisconsin Alumni Research Foundation Compositions and methods for improving cardiac structure and/or function
GB202108594D0 (en) 2021-06-16 2021-07-28 Cambridge Entpr Ltd Treatment or prevention of ischaemia reperfusion injury
WO2025125766A1 (en) 2023-12-12 2025-06-19 Cambridge Enterprise Limited Treatment or prevention of ischaemia reperfusion injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116337A1 (en) * 2010-06-08 2013-05-09 Richard M. LoPachin Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999021565A1 (en) 1997-10-24 1999-05-06 Cornell Research Foundation, Inc. Nutritional supplement for cerebral metabolic insufficiencies
EP1686979A4 (en) * 2003-11-07 2010-03-03 Jackson H M Found Military Med ACTIVATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION
WO2008039085A1 (en) 2006-09-28 2008-04-03 University Of Otago Triphenylphosphonium thionitrite nitric oxide donors
US9931313B2 (en) * 2012-04-04 2018-04-03 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
US10104882B2 (en) * 2013-04-29 2018-10-23 Montefiore Medical Center Methods and compositions for preventing and treating electrophile-mediated toxicities

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116337A1 (en) * 2010-06-08 2013-05-09 Richard M. LoPachin Methods and compositions for treating conditions mediated by oxidative stress or electrophilic environmental toxins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Inhibitors of Succinate: Quinone Reductase/Complex II Regulate Production of Mitochondrial Reactive Oxygen Species and Protect Normal Cells from Ischemic Damage but Induce Specific Cancer Cell Death;Stephen J.Ralph等;《Pharm Res》;20110824;2695-2730 *
Targeting nucleotide-requiring enzymes:implications for diazoxide-induced cardioprotection;Petras P.Dzeja等;《Am J Physiol Heart Circ Physiol》;20021205;H1048–H1056 *
The complex II inhibitor atpenin A5 protects against cardiac ischemia-reperfusion injury via activation of mitochondrial KATP channels;Andrew P.Wojtovich等;《Basic Res Cardiol》;20090226;121-129 *

Also Published As

Publication number Publication date
CN106714793A (zh) 2017-05-24
EP3164126A1 (en) 2017-05-10
WO2016001686A1 (en) 2016-01-07
EP3164126B1 (en) 2021-02-24
AU2015282424A1 (en) 2017-01-12
SG11201610588UA (en) 2017-01-27
US10603298B2 (en) 2020-03-31
CA2953709A1 (en) 2016-01-07
US20170135977A1 (en) 2017-05-18
GB201411937D0 (en) 2014-08-20
ZA201608844B (en) 2019-04-24
JP2017519020A (ja) 2017-07-13

Similar Documents

Publication Publication Date Title
CN106714793B (zh) 琥珀酸脱氢酶抑制剂(SDHi’s)
Chouchani et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Oh et al. Inhibition of pyruvate dehydrogenase kinase 4 ameliorates kidney ischemia-reperfusion injury by reducing succinate accumulation during ischemia and preserving mitochondrial function during reperfusion
Kimmoun et al. Hemodynamic consequences of severe lactic acidosis in shock states: from bench to bedside
US20220257767A1 (en) Ionic liquids for drug delivery
CN108623576B (zh) 用于抑制激酶活性的吲唑类化合物及其组合物及应用
WO2018027892A1 (en) Amino pyrimidine ssao inhibitors
KR20090130187A (ko) 점막염 및 체중 감소의 예방 및 치료를 위한 조성물 및 방법
JP6661533B2 (ja) ミトコンドリアを標的とするジカルボニル捕捉化合物
JP2022534872A (ja) 肝疾患の治療のための還元型ニコチンアミドリボシド
US11746089B2 (en) Compounds and methods for treating alcohol disorder
JP2022534869A (ja) 腎疾患を治療又は予防するための還元型ニコチンアミドリボシド
Maghsoud et al. Investigation of the inhibition mechanism of xanthine oxidoreductase by oxipurinol: a computational study
CN114096250B (zh) 红细胞生成性原卟啉症(epp)和x连锁原卟啉症(xlp)的疗法
US11730712B2 (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
Jin et al. Chiral recognition of CIAC001 isomers in regulating pyruvate kinase M2 and mitigating neuroinflammation
Cano-Peñalver et al. Renal integrin-linked kinase depletion induces kidney cGMP-axis upregulation: Consequences on basal and acutely damaged renal function
EA028518B1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
Prakash et al. Intracellular delivery of the P38 MAPK inhibitor SB202190 in renal tubular cells: a novel strategy to treat renal fibrosis
JP4912574B2 (ja) シトルリン血症治療剤
US12612365B2 (en) Compounds and methods for treating alcohol disorder
PT2379517E (pt) Derivados de arilciclopropilacetamida úteis como ativadores da glicocinase
Chouchani et al. 6HX, UK 7Department of Anesthesiology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA 8Institute of Cardiovascular & Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8TA, UK
KR20250103971A (ko) 신규 화합물 및 이의 비알콜성 지방간염의 예방 또는 치료 용도
WO2023081141A1 (en) Thymidylate synthase inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20201117

Address after: UK

Applicant after: United Kingdom Research and Innovation

Applicant after: CAMBRIDGE ENTERPRISE Ltd.

Address before: England

Applicant before: MEDICAL RESEARCH COUNCIL

Applicant before: CAMBRIDGE ENTERPRISE Ltd.

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20201201